Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTS-WBRT in Brain Metastases
NCT05013892Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2022
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in brain metastases, sponsored by Massachusetts General Hospital. Primary endpoints: Change in Patient Reported Quality of Life at 4 months and Change in Patient Reported Symptom Burden at 4 months. Started Feb 2022; status: recruiting.
02
Conditions
brain metastases
Beyond the preview
Go deeper on NCT05013892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05013892.